These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 19697195

  • 21. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial.
    Borna S, Sahabi N.
    Aust N Z J Obstet Gynaecol; 2008 Feb; 48(1):58-63. PubMed ID: 18275573
    [Abstract] [Full Text] [Related]

  • 22. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ.
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [Abstract] [Full Text] [Related]

  • 23. Oral micronized progesterone for prevention of preterm birth.
    Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S.
    Int J Gynaecol Obstet; 2009 Jan; 104(1):40-3. PubMed ID: 18929360
    [Abstract] [Full Text] [Related]

  • 24. The role of progesterone in maternal and fetal medicine.
    Di Renzo GC, Giardina I, Clerici G, Mattei A, Alajmi AH, Gerli S.
    Gynecol Endocrinol; 2012 Nov; 28(11):925-32. PubMed ID: 23057618
    [Abstract] [Full Text] [Related]

  • 25. The clinical utility of fetal fibronectin in the prediction of pre-term birth in a low socio-economic setting hospital in Ecuador.
    Díaz J, Chedraui P, Hidalgo L, Medina M.
    J Matern Fetal Neonatal Med; 2009 Feb; 22(2):89-93. PubMed ID: 19085632
    [Abstract] [Full Text] [Related]

  • 26. ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth.
    Society for Maternal Fetal Medicine Publications Committee.
    Obstet Gynecol; 2008 Oct; 112(4):963-5. PubMed ID: 18827143
    [No Abstract] [Full Text] [Related]

  • 27. Use of progesterone treatment for the prevention of recurrent preterm birth: identification of obstacles to change.
    Lim AC, Goossens A, Ravelli AC, Boer K, Bruinse HW, Mol BW.
    Am J Perinatol; 2010 Mar; 27(3):241-9. PubMed ID: 19823963
    [Abstract] [Full Text] [Related]

  • 28. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
    Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R.
    Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
    [Abstract] [Full Text] [Related]

  • 29. Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies.
    O'Brien JM, Lewis DF.
    J Reprod Med; 2009 Feb; 54(2):73-87. PubMed ID: 19301570
    [Abstract] [Full Text] [Related]

  • 30. Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies.
    de Oliveira LA, Brizot ML, Liao AW, Bittar RE, Francisco RP, Zugaib M.
    Acta Obstet Gynecol Scand; 2016 Apr; 95(4):436-43. PubMed ID: 26669629
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
    O'Brien JM.
    Am J Perinatol; 2012 Oct; 29(9):665-72. PubMed ID: 22773279
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
    Ventolini G, Duke J, Po W, Barhan S, Rhea D, Desch C, Istwan N, Stanziano G.
    J Reprod Med; 2008 Sep; 53(9):667-71. PubMed ID: 18839818
    [Abstract] [Full Text] [Related]

  • 36. Pregnancy outcomes following placement of elective, urgent and emergent cerclage.
    Nelson L, Dola T, Tran T, Carter M, Luu H, Dola C.
    J Matern Fetal Neonatal Med; 2009 Mar; 22(3):269-73. PubMed ID: 19330713
    [Abstract] [Full Text] [Related]

  • 37. Use of progesterone to prevent preterm birth at a tertiary care center.
    Bailit JL, Berkowitz R, Thorp JM, Cleary K, Hartmann KE, Mercer BM.
    J Reprod Med; 2007 Apr; 52(4):280-4. PubMed ID: 17506366
    [Abstract] [Full Text] [Related]

  • 38. Can sulfasalazine prevent infection-mediated pre-term birth in a murine model?
    Nath CA, Ananth CV, Smulian JC, Peltier MR.
    Am J Reprod Immunol; 2010 Feb; 63(2):144-9. PubMed ID: 20039863
    [Abstract] [Full Text] [Related]

  • 39. Therapeutic cerclage may be more efficacious in women who develop cervical insufficiency after a term delivery.
    Poggi SH, Vyas N, Pezzullo JC, Landy HJ, Ghidini A.
    Am J Obstet Gynecol; 2009 Jan; 200(1):68.e1-3. PubMed ID: 19019324
    [Abstract] [Full Text] [Related]

  • 40. Attitudes and practices regarding use of progesterone to prevent preterm births.
    Henderson ZT, Power ML, Berghella V, Lackritz EM, Schulkin J.
    Am J Perinatol; 2009 Aug; 26(7):529-36. PubMed ID: 19301227
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.